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Abstract
Background: Dystonia of the eyelids often spreads to affect other muscles in the craniocervical region. Certain blepharospasm-plus subphenotypes may be
clinically unique.
Methods: Seven subjects with the subphenotype of late-onset blepharospasm with apraxia of eyelid opening and cervical dystonia with predominant anterocollis
were identified from a database of over 1800 patients with primary dystonia.
Results: Blepharospasm was the first affected site in 6/7 subjects, followed by spread of the disease to the cervical muscles. Although four patients also had other
forms of dystonia (laryngeal, lower face), none showed spread outside the craniocervical region. A family history of dystonia was present in 4/7. No mutations were
identified in THAP1 or TOR1A. Overall, blepharospasm was difficult to treat, typically requiring both myectomy and substantial doses of botulinum toxin into the
pretarsal orbicularis oculi muscles. In one subject, anterocollis markedly improved after deep brain stimulation.
Discussion: Delineation and characterization of craniocervical dystonia subphenotypes may serve to guide genetic and therapeutic studies, in addition to clinical
interventions. The blepharospasm with apraxia of eyelid opening and anterocollis subphenotype can be therapeutically challenging.
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Introduction
Blepharospasm and cervical dystonia are two familiar manifesta-
tions of late-onset primary dystonia.1 Blepharospasm and cervical
dystonia may occur in isolation or as part of more extensive
anatomical involvement as segmental, multifocal, or generalized
dystonia.2 Late-onset primary dystonia is concentrated in the
craniocervical region of the body; the arms and legs are less frequently
affected.1,3 Dystonia of the craniocervical region may involve
contiguous or non-contiguous areas: (eyes and upper face) +/2 (lower
face) +/2 (jaw and tongue) +/2 (larynx) +/2 (neck). Although
various groupings of anatomical areas are possible in individual
patients during the course of their disease, certain patterns do appear
to be distinctive and have captured the attention of neurologists
for over 100 years: Meige syndrome, Brueghel syndrome, and
‘‘blepharospasm-plus,’’ for example.2,4,5 Unfortunately, the non-
possessive and possessive forms of Meige and Brueghel syndromes
have been ambiguously ascribed by neurologists to anatomical
variations of craniocervical dystonia that include the combination of
blepharospasm and involuntary movements of lower facial and/or
masticatory (jaw) muscles.2
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Late-onset primary focal dystonia, particularly blepharospasm, may
spread to adjoining or distant body parts.6–8 Most commonly, dystonia
with onset in the eyelids (blepharospasm) extends to the lower face and
masticatory muscles. In an important subset of patients, blephar-
ospasm may also spread to the neck. In a retrospective study of 78
patients with blepharospasm in the United States, 31% developed
manifest dystonia in the neck within 5 years of onset in the eyelids.6
Similar results were obtained in Italy, with 21% of 124 blepharospasm
patients showing spread to the neck with follow-up periods of up to 15
years.8 Unfortunately, these reports did not detail the severity and
positional characteristics of cervical dystonia in those subjects with
concomitant blepharospasm.
In subjects with primary dystonia limited to the cervical region,
isolated or predominant anterocollis is uncommon. In most neurology
practices, the majority of subjects with anterocollis have a neurode-
generative disorder, or secondary cervical dystonia due to neuroleptic
or antiemetic exposure.9–16 In two independent clinical series, 6.8%
and 25% of subjects with cervical dystonia exhibited anterocollis, most
commonly in combination with laterocollis and/or rotational torti-
collis.17,18 Conventionally, anterocollis can be difficult to treat with
botulinum toxin.19 In fact, most clinical studies of chemodenervation
for cervical dystonia have excluded subjects with isolated or
predominant anterocollis.20
Herein, we describe the demographics and clinical features of seven
patients with well-characterized primary late-onset segmental cranio-
cervical dystonia with a distinctive combination of blepharospasm with
apraxia of eyelid opening (AEO) and anterocollis. Given that the early-
onset primary dystonias driven by Mendelian inheritance tend to
exhibit characteristic clinical phenotypes, it is possible that subpheno-
types of late-onset dystonia are also driven by relatively specific genetic
variants and/or pathophysiological processes. Therefore, recognition
and characterization of subphenotypes may prove useful for genetic,
physiological, and therapeutic studies of dystonia.
Methods
Human studies were performed in accordance with institutional
review board guidelines, and all subjects gave informed consent for
genetic analyses, disclosure of medical and demographic information,
and use of photographs. A total of 170 subjects with segmental
dystonia were identified from our biorepository of over 1800 subjects
with primary dystonia.21 Among the group of subjects with segmental
dystonia, 114 had ‘‘blepharospasm-plus’’ subphenotypes of segmental
craniocervical dystonia, of whom seven had a distinctive combination
of anterocollis and blepharospasm. This subgroup was chosen for
presentation because of their relatively unique combination of clinical
features, including severe blepharospasm with AEO, limited or absent
response to sensory tricks, and absence of head and appendicular
tremors. Moreover, all patients were examined by the senior author
(MSL) and had long disease durations. In addition, subjects #1–#6
were treated by the senior author.
AEO was defined as a non-paretic inability to open the eyes
volitionally in the absence of overt visible contractions of the
orbicularis oculi (OO) muscles.22 Subjects with dystonia that had
spread outside the craniocervical region and variants of cervical
dystonia (torticollis, laterocollis or retrocollis) in which the severity of
rotational torticollis, laterocollis or lateral shift was equal to or
exceeded the degree of anterocollis are not presented in this report.
Sequence variants in exon 5 of TOR1A and THAP1 were excluded in
all seven subjects.3,23 All three subscales of the Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS) were administered by
the senior author before injections of botulinum toxin.24 Subjects were
also examined by the senior author for the presence of non-
physiological head and appendicular tremors (essential, dystonic, and
other).
Results
Table 1 summarizes the demographic and clinical data of the seven
subjects included in this study. In male subjects, dystonia first became
manifest in their fourth or early fifth decade (44–52 years of age). In
contrast, dystonia onset was 60 and 65 years, respectively, in the two
female patients. At the time of this report, dystonia duration was
between 7 and 15 years in all subjects. No subject showed clinical
evidence of Parkinsonism, ataxia, spasticity, or posterior cervical
(extensor) myopathy. Four patients had other sites of involvement, all
within the craniocervical region. During the course of their disease, all
subjects were given trials of oral agents for their dystonia and AEO.
Treatments included benzodiazepines, tetrabenazine, anticholinergic
agents, an analeptic (modafinil), a dopamine agonist (pramipexole),
levodopa, and muscle relaxants. In aggregate, oral pharmacotherapy
was only mildly beneficial in our cohort. Injections of onabotulinum-
toxin A were employed to relieve the symptoms of blepharospasm
(range: 47–110 units) and cervical dystonia (100–255 units). All
patients received injections into the pretarsal portions of the OO
muscles. Although complemented by the effects of botulinum toxin
injections, all subjects required surgical intervention in the form of OO
myectomy or blepharoplasty for adequate control of blepharospasm.
Subject #1 (Figure 1A–1C) is a Caucasian male with type II
diabetes and hyperlipidemia. Blepharospasm onset was mildly
asymmetrical, initially presenting in the left eye, followed by right
eye involvement a few months later. Cervical dystonia, manifest as
isolated anterocollis, appeared 5 years later. The severity of both
blepharospasm and anterocollis has progressed slowly over time.
Neither blepharospasm nor anterocollis has responded to trials of
clonazepam (maximum dosage: 1 mg t.i.d.), tetrabenazine (maximum
dosage: 25 mg t.i.d.), or trihexyphenidyl (maximum dosage: 5 mg
t.i.d.). Baclofen (10 mg b.i.d.) has been associated with mild
improvement in neck discomfort. This patient did not obtain
satisfactory clinical improvement with injections of onabotulinumtoxin
A and underwent limited OO myectomy at age 50 and, more
extensive, integrated upper eyelid myectomy25 at age 56. Bilateral
electromyographically (EMG)-guided injections of onabotulinumtoxin
A (178–255 units) into the sternocleidomastoid, scalene, levator
scapulae, longus colli, and longus capitis muscles were performed on
three occasions, but provided only minimal benefit. In contrast, since
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his second myectomy procedure, this patient’s blepharospasm and
AEO have responded well to injections of onabotulinumtoxin A
(8 units each upper eyelid pretarsal OO muscle, 47 units total).
Subject #2 (Figure 1D–1F), a Caucasian male, has had dry eye
symptoms that were treated with punctal plugs and, eventually, tear
duct cauterization. Mild but non-sustained improvements in both
Table 1. Demographic and Clinical Data
Data Subject #1 Subject #2 Subject #3 Subject #4 Subject #5 Subject #6 Subject #7
Age at most recent
evaluation (years)
60 62 71 59 73 58 66
Gender Male Male Female Male Female Male Male
BSP onset (years) 47 47 60 45 65 44 52
CD onset (years) 52 55 60 53 66 45 56
AEO Yes Yes Yes Yes Yes Yes Yes
Other dystonia Lower facial None Lower facial None None Laryngeal Lower facial
Time to spread
(years)
5 8 0 8 1 1 4
Duration of BSP
(years)
13 15 11 14 7 14 14
Pattern of spread BSPRCD BSPRCD BSP5CD BSPRCD BSPRCD BSPRCD BSPRCD
TWSTRS: total
score
28.25 31.25 20 30.5 30.75 16 32
TWSTRS: severity
score
17 15 15 13 20 13 14
TWSTRS: disability
score
4 9 6 9 6 3 13
TWSTRS: pain
score
7.25 7.25 1.5 8.5 4.75 0 5
TWSTRS: antero-
collis score
3 3 1 2 2 1 2
Cervical EMG Tonic Tonic Tonic Na Tonic Tonic Na
Relief from sen-
sory tricks





No No No No No No No








Abbreviations: BSP, blepharospasm; CD, cervical dystonia; EMG, electromyography; NA, not available or applicable; TWSTRS, Toronto Western Spasmodic Torticollis
Rating Scale.
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blepharospasm and cervical dystonia were noted with benzodiazepines
(clonazepam and alprazolam) and trihexyphenidyl. AEO showed no
reliable response to amphetamines. A bedtime dose of cyclobenzaprine
has helped to reduce nocturnal neck discomfort. Slight improvement
in AEO and blepharospasm was noted after a limited bilateral OO
myectomy and frontalis muscle sling procedure. Over the past 4 years,
this patient’s bilateral blepharospasm and AEO have responded
satisfactorily to injections of onabotulinumtoxinA (20 units each upper
eyelid pretarsal OO muscle, 94 units total). In contrast, cervical
dystonia with severe anterocollis has shown only modest improvements
with EMG-guided injections of onabotulinumtoxin A. Current
medical problems include hyperlipidemia, hypertension, and type II
diabetes mellitus. The patient’s sister had a single episode of bilateral
eyelid closure suggestive of blepharospasm that lasted approximately 3
months and resolved without specific treatment.
Subject #3, a Caucasian female with long-standing type I diabetes
mellitus, noticed the simultaneous onset of segmental craniocervical
dystonia (blepharospasm and cervical dystonia) at the age of 60, 2
weeks after the loss of her spouse. Blepharospasm and AEO did not
improve with clonazepam or modafinil, but have responded well to
injections of onabotulinumtoxin A (10 units each upper eyelid pretarsal
OO muscle, 73 units total). Peri-oral dystonia has been well controlled
with injections of onabotulinumtoxin A. Bilateral dermatochalasis was
treated with blepharoplasty. In general, better clinical results were
obtained with injections of onabotulinumtoxin A after blepharoplasty.
Cervical dystonia manifest as anterocollis with minimal left rotational
torticollis has responded well to EMG-guided injections of
onabotulinumtoxinA (up to 220 units).
Subject #4, an African-American male, gets limited relief of both
blepharospasm and cervical dystonia symptoms when he touches his
left lateral brow. He was treated with limited OO myectomy at 47
years of age. His blepharospasm and AEO have been successfully
managed with injections of onabotulinumtoxin A (16 units each upper
eyelid pretarsal OO muscle, 100 units total) and low-dose trihex-
yphenidyl (2–4 mg daily). He has declined injections of botulinum
toxin for treatment of his cervical dystonia, although it has become
more severe over the past several years. A younger sister has isolated
blepharospasm, reportedly responsive to injections of onabotulinum-
toxin A.
Subject #5 (Figure 1G–1I), a Caucasian female, did not benefit
from various combinations of medications including trihexyphenidyl,
clonazepam, modafanil, pramipexole, levodopa, and cyclobenzaprine.
Injections of onabotulinumtoxin A were moderately beneficial for
blepharospasm, but produced minimal improvement in cervical
dystonia. Additional reductions in blepharospasm severity and
improved responses to injections of onabotulinumtoxin A were
apparent after extensive integrated OO myectomy.25 However, owing
to progression of anterocollis and persistent need for onabotulinum-
toxin A injections to control blepharospasm, the subject underwent
bilateral microelectrode-guided placement of bilateral globus pallidus
pars interna (GPi) electrodes (Medtronic Kinetra). The benefits of
surgery were apparent within weeks, and with her current settings
Figure 1. Photographs of Three Subjects with Blepharospasm and Anterocollis Frontal, lateral, and posterior views of subjects #1 (A–C) and #2 (D–F).
Subject #5 before (H) and after ([I] 1 month; [J] 2 months) bilateral GPi DBS.
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(right GPi: case +, contact zero 2, 2.5 V, 90 ms pulse width, 130 Hz;
left GPi: case +, contact five 2, 2.4 V, 60 ms pulse width, 130 Hz),
there has been marked improvement of blepharospasm, AEO, and
cervical dystonia. She no longer requires injections of onabotulinum-
toxin A for blepharospasm/AEO, and her cervical dystonia is much
improved with only slight anterocollis and minimal residual pain.
Concomitant medical problems include restless legs syndrome, well
controlled with pramipexole, and gastroesophageal reflux disease.
Subject #6 is a Caucasian male who underwent bilateral limited
OO myectomy and frontalis muscle suspension owing to marginal
benefits of onabotulinumtoxinA injections. Subsequently, an inte-
grated upper eyelid myectomy25 was required to control blephar-
ospasm and AEO. Since the more extensive myectomy,
blepharospasm and AEO have responded well to injections (onabo-
tulinumtoxin A: 10 units each upper eyelid pretarsal OO muscle, 62
units total). This patient has also obtained consistently good results
with EMG-guided injections of onabotulinumtoxin A (up to 238 units)
for treatment of cervical dystonia. At age 53, this subject began to
exhibit episodic air hunger due to inspiratory laryngeal dystonia, a
diagnosis confirmed by a neurolaryngologist via historical information
in combination with videostroboscopy, direct laryngoscopy, and
laryngeal EMG. Modest improvements in laryngeal dystonia were
noted with EMG-guided injections of onabotulinumtoxin A into the
thyroarytenoid muscles. Ultimately, however, a tracheostomy was
required for symptom control. This patient’s father, now deceased, was
treated by the senior author for segmental craniocervical dystonia with
severe jaw-opening, cervical dystonia with rotational torticollis and
mild anterocollis, and very mild blepharospasm. Of note, subject #6’s
father did not show evidence of AEO or require injections for
treatment of blepharospasm.
Subject #7, a Caucasian male, has blepharospasm and cervical
dystonia manifest as isolated anterocollis. This patient has also
exhibited mild lower facial dystonia and AEO. Sensory tricks for
cervical dystonia (touching the side or back of the neck or chin) and
blepharospasm (touching a lateral eyebrow) provide limited relief. He
first underwent limited OO myectomy, which was followed by an
integrated upper eyelid myectomy,25 and then by lower eyelid
myectomy. More recently, he underwent OO myo-osseous fixation
with titanium screws,26 which has been associated with marked
subjective improvement in blepharospasm (,90%). For cervical
dystonia, he has obtained mild benefit from injections of onabotuli-
numtoxin A, performed without the use of EMG guidance. Family
history of dystonia includes multiple individuals in four consecutive
generations. The patient’s mother and one of three brothers have
blepharospasm. The patient’s maternal grandmother (deceased) and
one of two sisters (deceased) were reported to have had manifestations
of blepharospasm and lower facial dystonia.
Discussion
Late-onset primary dystonia most commonly begins in the
craniocervical region, and, although it may spread, tends to remain
isolated to the craniocervical region. Isolated or disproportionate
anterocollis is an uncommon form of primary cervical dystonia.
Additionally, no explicit data on the combination of blepharospasm
with subtypes of cervical dystonia have been published. Is the
combination of blepharospasm and anterocollis a phenotype of
segmental craniocervical dystonia that is physiologically, molecularly,
and genetically unique and distinct, or simply two different focal
manifestations of dystonia randomly affecting the same individual?
Even though our data and study design do not answer those
questions, the combination of blepharospasm and anterocollis does
show evidence, albeit uncontrolled, of characteristic clinical features,
including AEO, difficult-to-treat blepharospasm, absence of head
and appendicular tremors, frequent family history of dystonia, and
infrequent response to sensory tricks. From physiological and
evolutionary perspectives, eyelid closure and anterocollis provide a
coordinated motor plan to protect the eyes and face from oncoming
threats. Ultimately, n-dimensional cluster analysis of high-resolution
phenotypic data derived from a large multi-center cohort of subjects
with segmental craniocervical dystonia will be required to determine
whether creation of subphenotypes is scientifically valid. Although
potentially limited by recall and referral bias, our descriptive
analysis of a putative subphenotype does provide motivation for
more exacting characterization of primary dystonia, which, at
present, remains a clinical diagnosis, based solely on positive motor
manifestations.
Our descriptive, largely retrospective report has several limita-
tions. First, a rating scale for blepharospasm was not employed, and
the TWSTRS was not completed at each visit. Second, the
TWSTRS was not completed after washout of medications,
including botulinum toxin. Third, the collection of subjects
described herein may over-represent particularly complex cases
owing to referral bias. Fourth, we did not compare our cohort with
subjects with blepharospasm plus other forms of cervical dystonia.
Lastly, our data do not allow us unambiguously to argue that that
blepharospasm with AEO and anterocollis is a discrete entity rather
than a probabilistic collection of numerous possible combinations of
segmental craniocervical dystonia.
EMG showed tonic firing patterns in muscles known to generate
head flexion. In addition, none of our patients had evidence of a focal
or generalized myopathy with weakness of their posterior (extensor)
cervical musculature. The marked improvement of cervical dystonia
with deep brain stimulation (DBS) in subject #5, and positive response
to injections of onabotulinumtoxin A injections in subjects #2, #3,
and #6, also argue that the anterocollis noted in our cohort was
actually driven by dystonia of the cervical musculature.
Although the treatment of anterocollis is notoriously difficult, recent
advances in neuromodulation and botulinum toxin injection techni-
ques are encouraging. The success of GPi DBS in subject #5 offers
hope to patients similarly affected. Recent series support the efficacy of
DBS in patients with blepharospasm, cervical dystonia, and more
complex segmental craniocervical dystonia.27–29 However, the treat-
ment of cervical dystonia predominantly manifest as anterocollis has
not been explicitly reported. The use of EMG guidance for injections
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of botulinum toxin into the deep cervical musculature, particularly
when coupled with imaging (e.g., fluoroscopy or computed tomo-
graphy), may improve therapeutic outcomes.19,30
Concomitant AEO can be a major contributor to botulinum toxin
refractoriness in a subset of patients with blepharospasm.31 Although
the relative roles of the pretarsal OO and levator palpebrae (LP)
muscles in AEO is rarely established in routine clinical practice, a
significant percentage of patients do improve with pretarsal injections
of botulinum toxin and/or upper eyelid myectomy.31,32 Although
simultaneous OO and LP EMG was not performed in our cohort of
subjects, the positive response to injections of botulinum toxin suggests
that dystonic discharges of the OO muscle contributed to their
AEO.32,33 Alternatively, reduced contraction of the pretarsal OO
muscles and/or modulation of sensory pathways from orbital tissues
might have helped to normalize central feedback loops responsible for
activation of the LP muscle.33
Even after extensive upper eyelid myectomy, our patients still
required botulinum toxin injections for control of their blepharospasm
and AEO. A formal blepharospasm rating scale was not used to assess
our subjects since their condition often demanded injections of
botulinum toxin at intervals of less than 12 weeks, before the beneficial
effects of toxin had entirely waned. Anecdotally, anterocollis
contributed to disability by constricting normal access to upper
portions of the visual fields.
Spread of dystonia to other sites after onset as blepharospasm has
been well documented.6–8 For example, Svetel and colleagues7
observed 132 patients with primary blepharospasm and reported
spread of dystonia in 33.3%, with the second site being affected in 1.2
years, on average, and the highest chance of spread occurring within
the first 5 years after disease onset. In similar work, Abbruzzese et al.8
reported that only 3.4% of their patients demonstrated spread of
dystonia outside the craniocervical region. Based on these data, the
spread of blepharospasm to other craniocervical sites becomes
increasingly uncommon with the passage of time and spreading
outside the craniocervical region is distinctly unusual. Given the long
duration of blepharospasm in our cohort of subjects (7–15 years),
additional spread of dystonia is improbable.
Four of our subjects had a positive history of dystonia with variable
expressivity and reduced penetrance. We offer the hypothesis that
blepharospasm with AEO and anterocollis is a unique subphenotype of
adult-onset primary craniocervical dystonia that might be due to
distinct sequence variants in genes yet to be causally associated with
dystonia. In this regard, phenotype–genotype correlations are well
established in dystonia: early-onset leg involvement in DYT1 dystonia,
writer’s cramp and cervical dystonia in the myoclonus-dystonia
(DYT11), and predominant craniocervical manifestations in DYT6
dystonia.3 Craniocervical subphenotype–genotype correlations should
become possible as the genetic underpinnings of late-onset primary
dystonia are exposed. Physiologically, we should consider the
possibility that focal and segmental dystonias may be localized
manifestations of generalized neural dysfunction.
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